A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemiaSrđan Verstovšek, Josef T. Prchal, Ruben A. Mesa et al.|Leukemia Research|2017Cited by 41
Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)Srđan Verstovšek, Josef T. Prchal, Ruben A. Mesa et al.|Blood|2013Cited by 24
Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: Data analysis from a phase II study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer after chemotherapy for metastatic disease—MONARCH 1.Mark E. Boye, Gregory L. Price, Katherine Houghton et al.|Journal of Clinical Oncology|2017Cited by 3